Company news
Estrella Immunopharma, Inc. (NASDAQ:ESLA) news
Estrella Immunopharma, Inc. news releases on 6ix. Latest, Aug 3, 2026: Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical…
Press releases & updates
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
August 3, 2026
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
July 29, 2026
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma
July 24, 2026
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
May 5, 2026
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
March 22, 2026
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 9, 2026
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 3, 2026
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
January 6, 2026
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
January 5, 2026
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
December 4, 2025
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
November 3, 2025
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
October 6, 2025
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
June 5, 2025
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
June 3, 2025
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
February 21, 2025
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
September 26, 2024
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member
August 13, 2024